493 related articles for article (PubMed ID: 20030477)
1. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
Prescott WA; Nagel JL
Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
[TBL] [Abstract][Full Text] [Related]
2. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
3. Intravenous aminoglycoside usage and monitoring of patients with cystic fibrosis in Australia. What's new?
Soulsby N; Bell S; Greville H; Doecke C
Intern Med J; 2009 Aug; 39(8):527-31. PubMed ID: 19220547
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
Massie J; Cranswick N
J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
[TBL] [Abstract][Full Text] [Related]
5. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Smyth AR; Bhatt J; Nevitt SJ
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD002009. PubMed ID: 28349527
[TBL] [Abstract][Full Text] [Related]
6. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
7. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
[TBL] [Abstract][Full Text] [Related]
11. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Smyth AR; Bhatt J
Cochrane Database Syst Rev; 2012 Feb; (2):CD002009. PubMed ID: 22336782
[TBL] [Abstract][Full Text] [Related]
12. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Smyth AR; Bhatt J
Cochrane Database Syst Rev; 2010 Jan; (1):CD002009. PubMed ID: 20091528
[TBL] [Abstract][Full Text] [Related]
13. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
[TBL] [Abstract][Full Text] [Related]
14. Extended-interval aminoglycoside administration for children: a meta-analysis.
Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
[TBL] [Abstract][Full Text] [Related]
15. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.
Kim MJ; Bertino JS; Erb TA; Jenkins PL; Nafziger AN
J Clin Pharmacol; 2004 Jul; 44(7):696-707. PubMed ID: 15199074
[TBL] [Abstract][Full Text] [Related]
16. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis.
Graham AC; Mercier RC; Achusim LE; Pai MP
Ann Pharmacother; 2004 Jun; 38(6):936-41. PubMed ID: 15084688
[TBL] [Abstract][Full Text] [Related]
17. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring.
Croes S; Koop AH; van Gils SA; Neef C
Eur J Pharm Sci; 2012 Jan; 45(1-2):90-100. PubMed ID: 22094306
[TBL] [Abstract][Full Text] [Related]
19. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
Adeboyeku D; Jones AL; Hodson ME
J Cyst Fibros; 2011 Jan; 10(1):25-30. PubMed ID: 20920848
[TBL] [Abstract][Full Text] [Related]
20. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Smyth AR; Bhatt J
Cochrane Database Syst Rev; 2014 Feb; (2):CD002009. PubMed ID: 24497229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
